{
    "organizations": [],
    "uuid": "fc4178c0f3a7c00bb0422366689b97c75d9499cf",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-biofrontera-receives-favorable-chm/brief-biofrontera-receives-favorable-chmp-assessment-for-ameluz-in-combination-with-daylight-photodynamic-therapy-idUSFWN1PO0P3",
    "ord_in_thread": 0,
    "title": "BRIEF-Biofrontera Receives Favorable CHMP Assessment For Ameluz In Combination With Daylight Photodynamic Therapy",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 29 (Reuters) - BIOFRONTERA AG:\n* PTA-ADHOC: BIOFRONTERA AG: BIOFRONTERA RECEIVES FAVORABLE CHMP ASSESSMENT FOR AMELUZÂ® IN COMBINATION WITH DAYLIGHT PHOTODYNAMIC THERAPY\n* BASED ON POSITIVE OPINION, CO ANTICIPATES FORMAL APPROVAL BY EUROPEAN COMMISSION IN COMING WEEKS Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-01-29T19:26:00.000+02:00",
    "crawled": "2018-01-30T18:59:43.005+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "biofrontera",
        "ag",
        "biofrontera",
        "ag",
        "biofrontera",
        "receives",
        "favorable",
        "chmp",
        "assessment",
        "combination",
        "daylight",
        "photodynamic",
        "therapy",
        "based",
        "positive",
        "opinion",
        "co",
        "anticipates",
        "formal",
        "approval",
        "european",
        "commission",
        "coming",
        "week",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}